Lesaffre Human Care, supplier of quality ingredients from yeast and bacteria fermentation for the global human care markets, announced the recent publication of two scientific papers in the Medical Journal of Obstetrics and Gynecology and Beneficial Microbes, reiterating the beneficial effects of S. cerevisiae based ingredients in preventing vaginal infections and helping women manage their day to day intimate health.
As a key player in the human health sector and benefiting from the group’s 165 years of expertise, Lesaffre Human Care is committed to addressing some of the world’s most prevalent health challenges with innovative yeast and bacteria based ingredients backed by scientific evidence.
The company is therefore continuously investing in studies to advance global research on prominent topics such as women's health.
Lesaffre Human Care continues to investigate and deepen its understanding and expertise to provide data to support the efficacy of its ingredients.
“As an ingredient supplier, we believe that obtaining such scientific validation is paramount; which is why we are committed to standing out among ingredients suppliers by delivering second to none expert information to our customers and acting an industry leader in this regard.”
“We pledge to always provide safe ingredients vetted by the scientific community and that offer unique benefits backed by extensive research. In doing so, we seek to bring extra value to the health and nutrition industry while building trust and lasting relationships with our partners,” said Véronique Lhommet, Women’s Health Product Manager at Lesaffre Human Care.
To further its knowledge of S. cerevisiae CNCM I-3856 benefits on women’s intimate health, the company launched a clinical study. The goal was to research the effects of oral administration of this probiotic yeast as an adjuvant therapy in women suffering from vulvovaginal candidiasis (VVC).
Results, which spearheaded the publication in the Medical Journal of Obstetrics and Gynecology of one of the new scientific papers, showed that probiotic yeast S. cerevisiae CNCM I-3856 is “easy-to- use and well tolerated” and that “the probiotic yeast is efficient in controlling vaginal Candida proliferation after conventional treatment thus limiting VVC recurrence”.
“Writers also called our exclusive S. cerevisiae based probiotic a “natural breakthrough for vaginal health”, which is invaluable for more than 75% of women around the world who experience at least one episode of vaginal infection in their life, many of whom suffering from recurrence”, said Lhommet.
In addition to these findings, the peer-reviewed paper published in Beneficial Microbes this February revealed promising anti-fungal and anti-inflammatory properties for vaginal candidiasis therapy.
Researchers concluded: “the beneficial effect exerted by this S. cerevisiae based probiotic is the result of its interference with the expression of fungus virulence factors coupled with the modulation of the inflammatory response of the host.”
